Skip to content

Commit

Permalink
Merge pull request #699 from vaccineontology/issue-684-694
Browse files Browse the repository at this point in the history 
add two new vaccine adjuvant
  • Loading branch information
@zhengj2007
zhengj2007 authored Apr 9, 2024
2 parents 7d2c9a7 + 42754f1 commit f55eca2
Show file tree
Hide file tree
Showing 2 changed files with 358 additions and 263 deletions.
152 changes: 115 additions & 37 deletions src/modules/vaccine_adjuvant.owl
View file
Original file line number Diff line number Diff line change
Expand Up @@ -81,6 +81,12 @@



<!-- http://purl.obolibrary.org/obo/RO_0001000 -->

<owl:ObjectProperty rdf:about="http://purl.obolibrary.org/obo/RO_0001000"/>



<!-- http://purl.obolibrary.org/obo/VO_0005312 -->

<owl:ObjectProperty rdf:about="http://purl.obolibrary.org/obo/VO_0005312"/>
Expand All @@ -106,34 +112,7 @@

<!-- http://purl.obolibrary.org/obo/NCBITaxon_12264 -->

<owl:Class rdf:about="http://purl.obolibrary.org/obo/NCBITaxon_12264">
<rdfs:subClassOf>
<owl:Restriction>
<owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/RO_0000087"/>
<owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/VO_0000147"/>
</owl:Restriction>
</rdfs:subClassOf>
<rdfs:subClassOf>
<owl:Restriction>
<owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/VO_0005312"/>
<owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/VO_0005309"/>
</owl:Restriction>
</rdfs:subClassOf>
<obo:IAO_0000116>Chemical Nature: Nucleoprotein complex
Mechanism of Action: recognized by PRRs
Immune profile induced: Th1-biased
A particulate antigen delivery system.

Route of immunization: Intratumoral, intraperitoneally , IV
Point of Contact: Nicole Steinmetz, University of California, San Diego

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=26689376
https://www.ncbi.nlm.nih.gov/pubmed/?term=37844250</obo:IAO_0000116>
<obo:IAO_0000116>Logic axioms added by Jie Zheng in VO</obo:IAO_0000116>
<obo:IAO_0000233>https://github.com/vaccineontology/VO/issues/684</obo:IAO_0000233>
<obo:VO_0005328>93</obo:VO_0005328>
</owl:Class>
<owl:Class rdf:about="http://purl.obolibrary.org/obo/NCBITaxon_12264"/>



Expand Down Expand Up @@ -383,7 +362,7 @@ https://www.ncbi.nlm.nih.gov/pubmed/?term=37844250</obo:IAO_0000116>

<owl:Class rdf:about="http://purl.obolibrary.org/obo/VO_0000366">
<rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/VO_0001356"/>
<obo:IAO_0000115>A particulate antigen delivery system that contains particles made up of concentric lipid membranes containing phospholipids and other lipids in a bilayer configuration separated by aqueous compartments. It is a relatively stable but non-covalently-bound complex of saponin adjuvant Quil-A, cholesterol and amphipathic antigen in a molar ratio of approximately 1:1:1. The spectrum of viral capsid antigens and non-viral amphipathic antigens of relevance for human vaccination, incorporated into ISCOMs, comprises influenza, measles, rabies, gp340 from EB-virus, gp120 from HIV, Plasmodium falciparum and Trypanosoma cruzi.</obo:IAO_0000115>
<obo:IAO_0000115>A particulate antigen delivery system vaccine adjuvant that contains particles made up of concentric lipid membranes containing phospholipids and other lipids in a bilayer configuration separated by aqueous compartments. It is a relatively stable but non-covalently-bound complex of saponin adjuvant Quil-A, cholesterol and amphipathic antigen in a molar ratio of approximately 1:1:1. The spectrum of viral capsid antigens and non-viral amphipathic antigens of relevance for human vaccination, incorporated into ISCOMs, comprises influenza, measles, rabies, gp340 from EB-virus, gp120 from HIV, Plasmodium falciparum and Trypanosoma cruzi.</obo:IAO_0000115>
<obo:IAO_0000117>Oliver He</obo:IAO_0000117>
<obo:IAO_0000119>http://www.vaccination.inoz.com/adjuvants.html</obo:IAO_0000119>
<rdfs:label>liposome-based vaccine adjuvant</rdfs:label>
Expand Down Expand Up @@ -456,7 +435,7 @@ https://www.ncbi.nlm.nih.gov/pubmed/?term=37844250</obo:IAO_0000116>

<owl:Class rdf:about="http://purl.obolibrary.org/obo/VO_0000757">
<rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/VO_0001356"/>
<obo:IAO_0000115>A particulate antigen delivery system that consists of an assembly of antigens in multimeric form and presents an antigen to induce specific immunologic responses. The assembly is attached to a matrix with a built-in adjuvant, saponin. ISCOMs induce strong serum antibody responses, and are used as highly immunogenic forms of subunit vaccines. MeSH term: D20.215.894.860.449.</obo:IAO_0000115>
<obo:IAO_0000115>A particulate antigen delivery system vaccine adjuvant that consists of an assembly of antigens in multimeric form and presents an antigen to induce specific immunologic responses. The assembly is attached to a matrix with a built-in adjuvant, saponin. ISCOMs induce strong serum antibody responses, and are used as highly immunogenic forms of subunit vaccines. MeSH term: D20.215.894.860.449.</obo:IAO_0000115>
<obo:IAO_0000117>Oliver He</obo:IAO_0000117>
<obo:IAO_0000118>ISCOM</obo:IAO_0000118>
<obo:IAO_0000118>The immunostimulating complex</obo:IAO_0000118>
Expand Down Expand Up @@ -1415,7 +1394,7 @@ https://www.ncbi.nlm.nih.gov/pubmed/?term=37844250</obo:IAO_0000116>

<owl:Class rdf:about="http://purl.obolibrary.org/obo/VO_0001333">
<rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/VO_0001356"/>
<obo:IAO_0000115>A particulate antigen delivery system that is a vaccine adjuvant comprising cholesterol, phospholipid and saponin but without antigen.</obo:IAO_0000115>
<obo:IAO_0000115>A particulate antigen delivery system vaccine adjuvant that is a vaccine adjuvant comprising cholesterol, phospholipid and saponin but without antigen.</obo:IAO_0000115>
<obo:IAO_0000116>ISCOMATRIX is identical to ISCOMs except that it does not contain antigen. Ref: PMID: 17336431.</obo:IAO_0000116>
<obo:IAO_0000117>Samantha G. Sayers</obo:IAO_0000117>
<obo:IAO_0000119>PMID:19450632</obo:IAO_0000119>
Expand All @@ -1441,7 +1420,7 @@ https://www.ncbi.nlm.nih.gov/pubmed/?term=37844250</obo:IAO_0000116>

<owl:Class rdf:about="http://purl.obolibrary.org/obo/VO_0001335">
<rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/VO_0001356"/>
<obo:IAO_0000115>A particulate antigen delivery system that is albumin-heparin microparticles vaccine adjuvant that is prepared from albumin and heparin stabilized by cross-linking reaction with EDC.</obo:IAO_0000115>
<obo:IAO_0000115>A particulate antigen delivery system vaccine adjuvant that is albumin-heparin microparticles vaccine adjuvant that is prepared from albumin and heparin stabilized by cross-linking reaction with EDC.</obo:IAO_0000115>
<obo:IAO_0000117>Samantha G. Sayers</obo:IAO_0000117>
<obo:IAO_0000119>PMID:16734558</obo:IAO_0000119>
<rdfs:label>albumin-heparin microparticles vaccine adjuvant</rdfs:label>
Expand Down Expand Up @@ -1698,7 +1677,7 @@ https://www.ncbi.nlm.nih.gov/pubmed/?term=37844250</obo:IAO_0000116>
<obo:IAO_0000115>A vaccine adjuvant that serves as a particulate antigen delivery system.</obo:IAO_0000115>
<obo:IAO_0000117>Oliver He</obo:IAO_0000117>
<obo:IAO_0000117>Samantha G. Sayers</obo:IAO_0000117>
<rdfs:label>particulate antigen delivery system</rdfs:label>
<rdfs:label>particulate antigen delivery system vaccine adjuvant</rdfs:label>
</owl:Class>


Expand Down Expand Up @@ -2412,7 +2391,7 @@ Point of Contact: Carolina Lopez, University of Washington at St Louis</obo:IAO_
<obo:IAO_0000119>https://vac.niaid.nih.gov/view?id=30</obo:IAO_0000119>
<obo:IAO_0000119>https://www.ncbi.nlm.nih.gov/pubmed/?term=24099876</obo:IAO_0000119>
<obo:IAO_0000119>https://www.ncbi.nlm.nih.gov/pubmed/?term=29861183</obo:IAO_0000119>
<rdfs:label>DDO (Defective viral genome-Derived Oligonucleotide) vaccine adjuvant</rdfs:label>
<rdfs:label>defective viral genome-derived oligonucleotide vaccine adjuvant</rdfs:label>
</owl:Class>


Expand Down Expand Up @@ -5032,8 +5011,8 @@ https://clinicaltrials.gov/ct2/show/NCT02464163</obo:IAO_0000116>
<!-- http://purl.obolibrary.org/obo/VO_0006102 -->

<owl:Class rdf:about="http://purl.obolibrary.org/obo/VO_0006102">
<rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/VO_0000580"/>
<obo:IAO_0000115>A vaccine adjuvant which is an oligonucleotide.</obo:IAO_0000115>
<rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/VO_0006109"/>
<obo:IAO_0000115>A nucleic acid vaccine adjuvant that is primarily composed of oligonucleotide.</obo:IAO_0000115>
<obo:IAO_0000117>Jie Zheng</obo:IAO_0000117>
<rdfs:label>oligonucleotide vaccine adjuvant</rdfs:label>
</owl:Class>
Expand Down Expand Up @@ -5154,7 +5133,7 @@ Point of Contact: Ofer Levy, Precision Vaccines Program at Boston Children&apos;
<owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/VO_0005309"/>
</owl:Restriction>
</rdfs:subClassOf>
<obo:IAO_0000115>An emulsion vaccine adjuvant that targets on TLR-agonist for target. It is a nucleic acid-based adjuvant for chemical nature</obo:IAO_0000115>
<obo:IAO_0000115>An emulsion vaccine adjuvant that targets on TLR-agonist. It is a nucleic acid-based adjuvant for chemical nature</obo:IAO_0000115>
<obo:IAO_0000116>Chemical Nature: Nucleic acid, Emulsion
Mechanism of Action: Innate Immune Activation, preferential uptake by APCs
Immune profile induced: Th1-biased
Expand All @@ -5177,6 +5156,105 @@ https://clinicaltrials.gov/ct2/show/NCT05385991</obo:IAO_0000116>
<obo:VO_0005328>92</obo:VO_0005328>
<rdfs:label>ACM-CpG vaccine adjuvant</rdfs:label>
</owl:Class>



<!-- http://purl.obolibrary.org/obo/VO_0006107 -->

<owl:Class rdf:about="http://purl.obolibrary.org/obo/VO_0006107">
<rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/VO_0001356"/>
<rdfs:subClassOf>
<owl:Restriction>
<owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/RO_0000087"/>
<owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/VO_0000147"/>
</owl:Restriction>
</rdfs:subClassOf>
<rdfs:subClassOf>
<owl:Restriction>
<owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/RO_0001000"/>
<owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/NCBITaxon_12264"/>
</owl:Restriction>
</rdfs:subClassOf>
<rdfs:subClassOf>
<owl:Restriction>
<owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/VO_0005312"/>
<owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/VO_0005309"/>
</owl:Restriction>
</rdfs:subClassOf>
<obo:IAO_0000115>A particulate antigen delivery system vaccine adjuvant derived from Cowpea mosaic virus that is able to induce a Th1-biased response.</obo:IAO_0000115>
<obo:IAO_0000116>Chemical Nature: Nucleoprotein complex
Mechanism of Action: recognized by PRRs
Immune profile induced: Th1-biased

Route of immunization: Intratumoral, intraperitoneally , IV
Point of Contact: Nicole Steinmetz, University of California, San Diego

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=26689376
https://www.ncbi.nlm.nih.gov/pubmed/?term=37844250

Ongoing clinical trials:
none</obo:IAO_0000116>
<obo:IAO_0000117>Jie Zheng</obo:IAO_0000117>
<obo:IAO_0000117>Nicole Steinmetz</obo:IAO_0000117>
<obo:IAO_0000117>Nilufer kosar</obo:IAO_0000117>
<obo:IAO_0000117>Wolfgang Leitner</obo:IAO_0000117>
<obo:IAO_0000118>Cowpea mosaic virus</obo:IAO_0000118>
<obo:IAO_0000119>Pubmed:26689376</obo:IAO_0000119>
<obo:IAO_0000119>Pubmed:37844250</obo:IAO_0000119>
<obo:IAO_0000233>https://github.com/vaccineontology/VO/issues/684</obo:IAO_0000233>
<obo:VO_0005328>93</obo:VO_0005328>
<rdfs:label>cowpea mosaic virus vaccine adjuvant</rdfs:label>
</owl:Class>



<!-- http://purl.obolibrary.org/obo/VO_0006108 -->

<owl:Class rdf:about="http://purl.obolibrary.org/obo/VO_0006108">
<rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/VO_0006109"/>
<rdfs:subClassOf>
<owl:Restriction>
<owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/VO_0005312"/>
<owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/VO_0005311"/>
</owl:Restriction>
</rdfs:subClassOf>
<obo:IAO_0000115>A nucleic acid vaccine adjuvant that targets on TLR3 agonist to induce a mixed Th1/Th2 response.</obo:IAO_0000115>
<obo:IAO_0000116>Chemical Nature: dsRNA
Mechanism of Action: TLR3 agonist
Immune profile induced: Mixed Th1/Th2
category: nucleic-acid based adjuvant (TLR-agonist)
synthetic derivative of natural compound
Route of immunization: IM
Point of Contact: Seungbin Cha, NA Vaccine Institute

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=36761735
https://www.ncbi.nlm.nih.gov/pubmed/?term=38136298

Ongoing clinical trials:
none</obo:IAO_0000116>
<obo:IAO_0000117>Jie Zheng</obo:IAO_0000117>
<obo:IAO_0000117>Nilufer kosar</obo:IAO_0000117>
<obo:IAO_0000117>Seungbin Cha</obo:IAO_0000117>
<obo:IAO_0000118>Nexavant</obo:IAO_0000118>
<obo:IAO_0000119>Pubmed:36761735</obo:IAO_0000119>
<obo:IAO_0000119>Pubmed:38136298</obo:IAO_0000119>
<obo:IAO_0000233>https://github.com/vaccineontology/VO/issues/694</obo:IAO_0000233>
<obo:VO_0005328>94</obo:VO_0005328>
<rdfs:label>nexavant vaccine adjuvant</rdfs:label>
</owl:Class>



<!-- http://purl.obolibrary.org/obo/VO_0006109 -->

<owl:Class rdf:about="http://purl.obolibrary.org/obo/VO_0006109">
<rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/VO_0000580"/>
<obo:IAO_0000115>A vaccine adjuvant that is primarily composed of nucleic acid.</obo:IAO_0000115>
<obo:IAO_0000117>Jie Zheng</obo:IAO_0000117>
<rdfs:label>nucleic acid vaccine adjuvant</rdfs:label>
</owl:Class>
</rdf:RDF>


Expand Down
Loading

0 comments on commit f55eca2

Please sign in to comment.